Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 44Sarcoma 2Lymphoid 2Dermatologic 2Breast 2Other solid neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Classical hematology 1

Conditions

Head and Neck Neoplasms 2603Squamous Cell Carcinoma of Head and Neck 1880Thyroid Neoplasms 704Nasopharyngeal Carcinoma 627Carcinoma, Non-Small-Cell Lung 477Mouth Neoplasms 424Breast Neoplasms 383Neoplasms 381Oropharyngeal Neoplasms 359Melanoma 339Lung Neoplasms 318Colorectal Neoplasms 307Carcinoma, Squamous Cell 282Neoplasm Metastasis 255Ovarian Neoplasms 254Laryngeal Neoplasms 253Salivary Gland Neoplasms 236Uterine Cervical Neoplasms 234Stomach Neoplasms 223Esophageal Neoplasms 222Nasopharyngeal Neoplasms 221Pancreatic Neoplasms 213Prostatic Neoplasms 203Carcinoma, Renal Cell 201Thyroid Nodule 179Thyroid Cancer, Papillary 178Urinary Bladder Neoplasms 163Sarcoma 160Recurrence 143Hypopharyngeal Neoplasms 143

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 2 × Head & Neck × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡